STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma: We decided to determine the effect of NT1721 on STAT3 activation since several reports show that GLI1 inhibition or knockdown decreased phosho-STAT3 (pSTAT3) levels in T cell lymphomas and that pSTAT3 may be an important driver of CTCL, especially in advanced disease [26].